基线及中期PET功能成像可有效对周围T细胞淋巴瘤患者进行风险分层
研究纳入112例接受CHOP/CHOP样方案并计划自体移植巩固的周围T细胞淋巴瘤(PTCL)患者,回顾基线(n=93)和中期(4周期后,n=99)PET,计算基线总代谢肿瘤体积(TMTV),并按5点评分(i5PS)和标准化摄取值百分比变化评估中期PET(iPET)反应。多因素分析显示高基线TMTV预测更差总生存(HR 6.025,P=.022)和无事件生存(HR 3.861,P=.005);i5PS 4-5分且PIT>1者4年OS和EFS均为0%。作者认为iPET联合临床参数有助于风险分层,但需前瞻性研究证实。
要点
- 高基线TMTV(>125 cm3)是多因素分析中OS(HR 6.025,P=.022)和EFS(HR 3.861,P=.005)的独立不良预后因素。
- i5PS 1-3分患者中位OS 104个月、EFS 64个月,长于i5PS 4-5分患者的19个月和11个月(P<.001)。
- 控制IPI和PIT后,i5PS对EFS(HR 3.400,95%CI 1.750-6.750,P<.001)和OS(HR 10.243,95%CI 4.052-25.891,P<.001)仍独立预后。
核心结论
- iPET联合临床参数有助于对PTCL患者进行风险分层,并可为风险适应治疗策略提供信息;作者指出需前瞻性研究证实这些发现。
研究设计与样本
- 研究纳入112例连续接受CHOP/CHOP样方案并计划自体移植巩固的PTCL患者,回顾性重新评估基线(n=93)和中期(4周期后,n=99)PET图像,计算基线TMTV;iPET反应按5点评分(i5PS)和标准化摄取值百分比变化分级。
主要发现
- 单因素分析中,EFS的预测因素包括PIT>1(HR 1.83,P=.021)、IPI>3(HR 2.01,P=.021)、高TMTV(>125 cm3;HR 3.92,P=.003)和iPET阳性(HR 3.57,P<.001)。
- 多因素分析中,高基线TMTV预测更差OS(HR 6.025,P=.022)和EFS(HR 3.861,P=.005)。
- i5PS 1-3分患者中位OS和EFS分别为104个月和64个月,i5PS 4-5分患者分别为19个月和11个月(P<.001)。
- i5PS 1-3分且PIT≤1者4年OS和EFS分别为85%和62%;i5PS 4-5分且PIT>1者4年OS和EFS均为0%(P<.001)。
- 控制IPI和PIT后,i5PS对EFS(HR 3.400,95%CI 1.750-6.750,P<.001)和OS(HR 10.243,95%CI 4.052-25.891,P<.001)仍独立预后。
临床怎么用
- 作者认为,iPET联合临床参数有助于对PTCL患者进行风险分层,并可为风险适应治疗策略提供信息;作者指出需前瞻性研究证实这些发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of peripheral T-cell lymphoma (PTCL) is heterogenous. Baseline or interim imaging characteristics may inform risk-adapted treatment paradigms. We identified 112 patients with PTCL who were consecutively treated with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)/CHOP-like regimens with the intent to consolidate with an autologous transplant. Baseline (n = 93) and interim (after 4 cycles, n = 99) positron emission tomography (PET) images were reevaluated, and we calculated baseline total metabolic tumor volume (TMTV). Interim PET (iPET) responses were graded visually by 5-point score (i5PS) and by percentage change of standardized uptake value. By univariate analysis, predictors of event-free survival (EFS) included Prognostic Index for Peripheral TCL (PIT) higher than 1 (hazard ratio [HR], 1.83; P = .021), International Prognostic Index (IPI) higher than 3 (HR, 2.01; P = .021), high TMTV (>125 cm3; HR, 3.92; P = .003), and positive iPET (HR, 3.57; P < .001). By multivariate analysis, high baseline TMTV predicted worse overall survival (OS; HR, 6.025; P = .022) and EFS (HR, 3.861; P = .005). Patients with i5PS of 1 to 3 had a longer median OS and EFS (104 months, 64 months) than those with i5PS of 4 to 5 (19 months, 11 months; P < .001). Four-year OS and EFS for patients with i5PS of 1 to 3 and PIT of 1 or less were 85% and 62%, respectively. However, 4-year OS and EFS for those with i5PS of 4 to 5 and PIT higher than 1 were both 0% (P < .001). In multivariate analysis, after controlling for IPI and PIT, i5PS was independently prognostic for EFS (HR, 3.400 95% confidence interval, 1.750-6.750; P < .001) and OS (HR, 10.243; 95% confidence interval, 4.052-25.891; P < .001). In conjunction with clinical parameters, iPET helps risk stratify patients with PTCL and could inform risk-adapted treatment strategies. Prospective studies are needed to confirm these findings.
引用
- Mehta-Shah N, Ito K, Bantilan K, et al. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Adv. 2019. PMID: 30670535. doi:10.1182/bloodadvances.2018024075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。